{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T17:19:54Z","timestamp":1782926394900,"version":"3.54.5"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,9,12]],"date-time":"2015-09-12T00:00:00Z","timestamp":1442016000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001349","name":"National Medical Research Council (SG)","doi-asserted-by":"publisher","award":["NMRC\/STaR\/013\/2012"],"award-info":[{"award-number":["NMRC\/STaR\/013\/2012"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s12072-015-9661-x","type":"journal-article","created":{"date-parts":[[2015,9,12]],"date-time":"2015-09-12T09:18:08Z","timestamp":1442049488000},"page":"277-285","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Advances in therapeutics for chronic hepatitis B"],"prefix":"10.1007","volume":"10","author":[{"given":"Ninghan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Bertoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,9,12]]},"reference":[{"issue":"6","key":"9661_CR1","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2011.12.061","volume":"142","author":"HB El-Serag","year":"2012","unstructured":"El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012;142(6):1264\u20131273.e1","journal-title":"Gastroenterology"},{"issue":"12","key":"9661_CR2","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.vaccine.2011.12.116","volume":"30","author":"JJ Ott","year":"2012","unstructured":"Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012;30(12):2212\u20132219","journal-title":"Vaccine"},{"key":"9661_CR3","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0168-8278(12)60009-9","volume":"56","author":"CR Lope De","year":"2012","unstructured":"De Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Management of HCC. J Hepatol 2012;56:75\u201387","journal-title":"J Hepatol"},{"issue":"2","key":"9661_CR4","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/00000441-197509000-00025","volume":"270","author":"MR Hilleman","year":"1975","unstructured":"Hilleman MR, Buynak EB, Roehm RR, Tytell AA, Bertland AU, Lampson GP. Purified and inactivated human hepatitis B vaccine: progress report. Am J Med Sci 1975;270(2):401\u2013404","journal-title":"Am J Med Sci"},{"issue":"2","key":"9661_CR5","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1365-2893.2003.00487.x","volume":"11","author":"D Lavanchy","year":"2004","unstructured":"Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004;11(2):97\u2013107","journal-title":"J Viral Hepat"},{"issue":"7","key":"9661_CR6","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1473-3099(02)00315-8","volume":"2","author":"J-H Kao","year":"2002","unstructured":"Kao J-H, Chen D-S. Global control of hepatitis B virus infection. Lancet Infect Dis 2002;2(7):395\u2013403","journal-title":"Lancet Infect Dis"},{"issue":"15\u201316","key":"9661_CR7","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1016\/S0264-410X(00)00410-2","volume":"19","author":"P Rendi-Wagner","year":"2001","unstructured":"Rendi-Wagner P, Kundi M, Stemberger H, Wiedermann G, Holzmann H, Hofer M, et al. Antibody-response to three recombinant hepatitis B vaccines: comparative evaluation of multicenter travel-clinic based experience. Vaccine 2001;19(15\u201316):2055\u20132060","journal-title":"Vaccine"},{"issue":"2","key":"9661_CR8","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jhep.2007.11.011","volume":"48","author":"G Fattovich","year":"2008","unstructured":"Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008;48(2):335\u2013352","journal-title":"J Hepatol"},{"issue":"6","key":"9661_CR9","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/hep.21896","volume":"46","author":"A Schulze","year":"2007","unstructured":"Schulze A, Gripon P, Urban S. Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans. Hepatology 2007;46(6):1759\u20131768","journal-title":"Hepatology"},{"key":"9661_CR10","first-page":"1","volume":"2012","author":"H Yan","year":"2012","unstructured":"Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife 2012;2012:1\u201328","journal-title":"Elife"},{"key":"9661_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/j.gastro.2013.11.019","volume":"146","author":"Y Ni","year":"2014","unstructured":"Ni Y, Lempp FA, Mehrle S, Nkongolo S, Kaufman C, F\u00e4lth M, et al. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology 2014;146:1\u201314","journal-title":"Gastroenterology"},{"issue":"3","key":"9661_CR12","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jhep.2004.12.015","volume":"42","author":"F Zoulim","year":"2005","unstructured":"Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol 2005;42(3):302\u2013308","journal-title":"J Hepatol"},{"issue":"7","key":"9661_CR13","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1053\/j.gastro.2004.03.018","volume":"126","author":"B Werle-Lapostolle","year":"2004","unstructured":"Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004;126(7):1750\u20131758","journal-title":"Gastroenterology"},{"issue":"23","key":"9661_CR14","doi-asserted-by":"crossref","first-page":"21713","DOI":"10.1074\/jbc.M501564200","volume":"280","author":"T Kimura","year":"2005","unstructured":"Kimura T, Ohno N, Terada N, Rokuhara A, Matsumoto A, Yagi S, et al. Hepatitis B virus DNA-negative dane particles lack core protein but contain a 22-kDa precore protein without C-terminal arginine-rich domain. J Biol Chem 2005;280(23):21713\u201321719","journal-title":"J Biol Chem"},{"issue":"7","key":"9661_CR15","doi-asserted-by":"crossref","first-page":"4269","DOI":"10.1128\/JVI.70.7.4269-4274.1996","volume":"70","author":"T Gerelsaikhan","year":"1996","unstructured":"Gerelsaikhan T, Tavis J, Bruss V. Hepatitis B virus nucleocapsid envelopment does not occur without genomic DNA synthesis. J Virol 1996;70(7):4269\u20134274","journal-title":"J Virol"},{"key":"9661_CR16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3851\/IMP1619","volume":"15","author":"S Locarnini","year":"2010","unstructured":"Locarnini S, Zoulim F. Molecular genetics of HBV infection. Antivir Ther 2010;15:3\u201314","journal-title":"Antivir Ther"},{"issue":"6","key":"9661_CR17","doi-asserted-by":"crossref","first-page":"6669","DOI":"10.1073\/pnas.0401771101","volume":"101","author":"S Wieland","year":"2004","unstructured":"Wieland S, Thimme R, Purcell RH, Chisari FV. Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci USA 2004;101(6):6669\u20136674","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"9661_CR18","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1053\/j.gastro.2009.06.054","volume":"137","author":"C Dunn","year":"2009","unstructured":"Dunn C, Peppa D, Khanna P, Nebbia G, Jones M, Brendish N, et al. Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology 2009;137(4):1289\u20131300","journal-title":"Gastroenterology"},{"issue":"Suppl 3","key":"9661_CR19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3851\/IMP1620","volume":"15","author":"A Bertoletti","year":"2010","unstructured":"Bertoletti A, Maini MK, Ferrari C. The host-pathogen interaction during HBV infection: immunological controversies. Antivir Ther 2010;15(Suppl 3):15\u201324","journal-title":"Antivir Ther"},{"issue":"2","key":"9661_CR20","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1172\/JCI58847","volume":"122","author":"L Belloni","year":"2012","unstructured":"Belloni L, Allweiss L, Guerrieri F, Pediconi N, Volz T, Pollicino T, et al. IFN-\u03b1 inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest 2012;122(2):529\u2013537","journal-title":"J Clin Invest"},{"issue":"7","key":"9661_CR21","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1053\/j.gastro.2013.02.003","volume":"144","author":"RE Lanford","year":"2013","unstructured":"Lanford RE, Guerra B, Chavez D, Giavedoni L, Hodara VL, Brasky KM, et al. GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology 2013;144(7):1508\u20131517e.1\u201310","journal-title":"Gastroenterology"},{"issue":"284","key":"9661_CR22","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1126\/science.284.5415.825","volume":"1999","author":"LG Guidotti","year":"1999","unstructured":"Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999;1999(284):825\u2013829","journal-title":"Science"},{"issue":"10","key":"9661_CR23","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.4049\/jimmunol.145.10.3442","volume":"145","author":"C Ferrari","year":"1990","unstructured":"Ferrari C, Penna A, Bertoletti A, Valli A, Antoni AD, Giuberti T, et al. Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. J Immunol 1990;145(10):3442\u20133449","journal-title":"J Immunol"},{"issue":"5","key":"9661_CR24","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1172\/JCI3731","volume":"102","author":"C Boni","year":"1998","unstructured":"Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998;102(5):968\u2013975","journal-title":"J Clin Invest"},{"issue":"6","key":"9661_CR25","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S0016-5085(99)70289-1","volume":"117","author":"MK Maini","year":"1999","unstructured":"Maini MK, Boni C, Ogg GS, King AS, Reignat S, Lee CK, et al. Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection. Gastroenterology 1999;117(6):1386\u20131396","journal-title":"Gastroenterology"},{"issue":"1","key":"9661_CR26","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1128\/JVI.77.1.68-76.2003","volume":"77","author":"R Thimme","year":"2003","unstructured":"Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann KA, Purcell RH, et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003;77(1):68\u201376","journal-title":"J Virol"},{"issue":"6144","key":"9661_CR27","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1136\/bmj.2.6144.1056","volume":"2","author":"A Alberti","year":"1978","unstructured":"Alberti A, Diana S, Sculard GH, Eddleston AL, Williams R. Detection of a new antibody system reacting with Dane particles in hepatitis B virus infection. Br Med J 1978;2(6144):1056\u20131058","journal-title":"Br Med J"},{"issue":"11","key":"9661_CR28","doi-asserted-by":"crossref","first-page":"5707","DOI":"10.1128\/JVI.78.11.5707-5719.2004","volume":"78","author":"GJM Webster","year":"2004","unstructured":"Webster GJM, Reignat S, Brown D, Ogg GS, Jones L, Seneviratne SL, et al. Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol 2004;78(11):5707\u20135719","journal-title":"J Virol"},{"issue":"8","key":"9661_CR29","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1128\/JVI.02844-06","volume":"81","author":"C Boni","year":"2007","unstructured":"Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T, et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 2007;81(8):4215\u20134225","journal-title":"J Virol"},{"issue":"5","key":"9661_CR30","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1172\/JCI33402","volume":"118","author":"AR Lopes","year":"2008","unstructured":"Lopes AR, Kellam P, Das A, Dunn C, Kwan A, Turner J, et al. Bim-mediated deletion of antigen-specific CD8 T cells in patients unable to control HBV infection. J Clin Invest 2008;118(5):1835\u20131845","journal-title":"J Clin Invest"},{"issue":"6","key":"9661_CR31","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1002\/hep.23936","volume":"52","author":"B Raziorrouh","year":"2010","unstructured":"Raziorrouh B, Schraut W, Gerlach T, Nowack D, Gr\u00fcner NH, Ulsenheimer A, et al. The immunoregulatory role of CD244 in chronic hepatitis B infection and its inhibitory potential on virus-specific CD8+ T-cell function. Hepatology 2010;52(6):1934\u20131947","journal-title":"Hepatology"},{"issue":"5","key":"9661_CR32","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1002\/hep.24249","volume":"53","author":"A Schurich","year":"2011","unstructured":"Schurich A, Khanna P, Lopes AR, Han KJ, Peppa D, Micco L, et al. Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection. Hepatology 2011;53(5):1494\u20131503","journal-title":"Hepatology"},{"issue":"6","key":"9661_CR33","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/hep.510250631","volume":"25","author":"GK Lau","year":"1997","unstructured":"Lau GK, Lok AS, Liang RH, Lai CL, Chiu EK, Lau YL, et al. Clearance of hepatitis B surface antigen after bone marrow transplantation: role of adoptive immunity transfer. Hepatology 1997;25(6):1497\u20131501","journal-title":"Hepatology"},{"issue":"6","key":"9661_CR34","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/sj.bmt.1702571","volume":"26","author":"Y Ilan","year":"2000","unstructured":"Ilan Y, Nagler A, Zeira E, Adler R, Slavin S, Shouval D. Maintenance of immune memory to the hepatitis B envelope protein following adoptive transfer of immunity in bone marrow transplant recipients. Bone Marrow Transplant 2000;26(6):633\u2013638","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"9661_CR35","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2009.08.063","volume":"137","author":"F Zoulim","year":"2009","unstructured":"Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009;137(5):1593\u20131608.e1\u20132","journal-title":"Gastroenterology"},{"issue":"7","key":"9661_CR36","doi-asserted-by":"crossref","first-page":"2169.e4","DOI":"10.1053\/j.gastro.2009.03.006","volume":"136","author":"P Marcellin","year":"2009","unstructured":"Marcellin P, Bonino F, Lau GKK, Farci P, Yurdaydin C, Piratvisuth T, et al. Sustained response of hepatitis B e antigen-negative patients 3\u00a0years after treatment with peginterferon alfa-2a. Gastroenterology 2009;136(7):2169\u20132179.e1\u20134","journal-title":"Gastroenterology"},{"issue":"3","key":"9661_CR37","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/hep.26436","volume":"58","author":"MJ Sonneveld","year":"2013","unstructured":"Sonneveld MJ, Hansen BE, Piratvisuth T, Jia J-D, Zeuzem S, Gane E, et al. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology 2013;58(3):872\u2013880","journal-title":"Hepatology"},{"issue":"6","key":"9661_CR38","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.bpg.2008.11.007","volume":"22","author":"EHCJ Buster","year":"2008","unstructured":"Buster EHCJ, Schalm SW, Janssen HLA. Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues. Best Pract Res Clin Gastroenterol 2008;22(6):1093\u20131108","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"9959","key":"9661_CR39","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/S0140-6736(14)60220-8","volume":"384","author":"C Tr\u00e9po","year":"2014","unstructured":"Tr\u00e9po C, Chan HLY, Lok A. Hepatitis B virus infection. Lancet 2014;384(9959):2053\u20132063","journal-title":"Lancet"},{"issue":"3","key":"9661_CR40","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1128\/JVI.79.3.1613-1622.2005","volume":"79","author":"P Gripon","year":"2005","unstructured":"Gripon P, Cannie I, Urban S. Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein. J Virol 2005;79(3):1613\u20131622","journal-title":"J Virol"},{"issue":"3","key":"9661_CR41","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nbt1389","volume":"26","author":"J Petersen","year":"2008","unstructured":"Petersen J, Dandri M, Mier W, L\u00fctgehetmann M, Volz T, von Weizs\u00e4cker F, et al. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol 2008;26(3):335\u2013341","journal-title":"Nat Biotechnol"},{"issue":"5","key":"9661_CR42","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jhep.2012.12.008","volume":"58","author":"T Volz","year":"2013","unstructured":"Volz T, Allweiss L, Ben M, Barek M, Warlich M, Lohse AW, et al. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol 2013;58(5):861\u2013867","journal-title":"J Hepatol"},{"issue":"10","key":"9661_CR43","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1038\/mt.2013.170","volume":"21","author":"K Bloom","year":"2013","unstructured":"Bloom K, Ely A, Mussolino C, Cathomen T, Arbuthnot P. Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases. Mol Ther 2013;21(10):1889\u20131897","journal-title":"Mol Ther"},{"issue":"5","key":"9661_CR44","doi-asserted-by":"crossref","first-page":"e97579","DOI":"10.1371\/journal.pone.0097579","volume":"9","author":"ND Weber","year":"2014","unstructured":"Weber ND, Stone D, Sedlak RH, De Silva Feelixge HS, Roychoudhury P, Schiffer JT, et al. AAV-mediated delivery of zinc finger nucleases targeting hepatitis B virus inhibits active replication. PLoS ONE 2014;9(5):e97579","journal-title":"PLoS ONE"},{"issue":"11","key":"9661_CR45","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/nprot.2013.143","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc 2013;8(11):2281\u20132308","journal-title":"Nat Protoc"},{"issue":"6","key":"9661_CR46","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.cell.2014.05.010","volume":"157","author":"PD Hsu","year":"2014","unstructured":"Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell 2014;157(6):1262\u20131278","journal-title":"Cell"},{"key":"9661_CR47","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1038\/mtna.2014.68","volume":"3","author":"C Seeger","year":"2014","unstructured":"Seeger C, Sohn JA. Targeting hepatitis B virus with CRISPR\/Cas9. Mol Ther Acids 2014;3:e216","journal-title":"Mol Ther Acids"},{"key":"9661_CR48","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1038\/mtna.2014.38","volume":"3","author":"S-R Lin","year":"2014","unstructured":"Lin S-R, Yang H-C, Kuo Y-T, Liu C-J, Yang T-Y, Sung K-C, et al. The CRISPR\/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo. Mol Ther Nucleic Acids 2014;3:e186","journal-title":"Mol Ther Nucleic Acids"},{"key":"9661_CR49","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.virol.2014.12.001","volume":"476","author":"EM Kennedy","year":"2015","unstructured":"Kennedy EM, Bassit LC, Mueller H, Kornepati AVR, Bogerd HP, Nie T, et al. Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR\/Cas RNA-guided DNA endonuclease. Virology 2015;476:196\u2013205","journal-title":"Virology"},{"issue":"3","key":"9661_CR50","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/hep.21282","volume":"44","author":"K Wursthorn","year":"2006","unstructured":"Wursthorn K, Lutgehetmann M, Dandri M, Volz T, Buggisch P, Zollner B, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006;44(3):675\u2013684","journal-title":"Hepatology"},{"key":"9661_CR51","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1243462","volume":"343","author":"J Lucifora","year":"2014","unstructured":"Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 2014;343:1221\u20131228","journal-title":"Science"},{"issue":"5665","key":"9661_CR52","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1126\/science.1092066","volume":"303","author":"P Turelli","year":"2004","unstructured":"Turelli P, Mangeat B, Jost S, Vianin S, Trono D. Inhibition of hepatitis B virus replication by APOBEC3G. Science 2004;303(5665):1829","journal-title":"Science"},{"issue":"18","key":"9661_CR53","doi-asserted-by":"crossref","first-page":"5797","DOI":"10.1073\/pnas.1502390112","volume":"112","author":"G Ebert","year":"2015","unstructured":"Ebert G, Preston S, Allison C, Cooney J, Toe JG, Stutz MD, et al. Cellular inhibitor of apoptosis proteins prevent clearance of hepatitis B virus. Proc Natl Acad Sci USA 2015;112(18):5797\u20135802","journal-title":"Proc Natl Acad Sci USA"},{"issue":"18","key":"9661_CR54","first-page":"201502400","volume":"112","author":"G Ebert","year":"2015","unstructured":"Ebert G, Allison C, Preston S, Cooney J, Toe JG, Stutz MD, et al. Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis. Proc Natl Acad Sci 2015;112(18):201502400","journal-title":"Proc Natl Acad Sci"},{"issue":"5","key":"9661_CR55","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/mt.2013.31","volume":"21","author":"CI Wooddell","year":"2013","unstructured":"Wooddell CI, Rozema DB, Hossbach M, John M, Hamilton HL, Chu Q, et al. Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Mol Ther 2013;21(5):973\u2013985","journal-title":"Mol Ther"},{"key":"9661_CR56","doi-asserted-by":"crossref","unstructured":"Klumpp K, Shimada T, Allweiss L, Volz T, Luetgehetman M, Flores O et al. High antiviral activity of the HBV core inhibitor NVR 3-778 in the humanized UPA\/SCID mouse model. In: EASL, The International Liver Congress 2015; 2015. p. S250","DOI":"10.1016\/S0168-8278(15)30134-3"},{"key":"9661_CR57","doi-asserted-by":"crossref","unstructured":"Lam A, Espiritu C, Flores O, Hartman G, Klumpp K. Effect of the combination of the HBV core inhibitor NVR 3-778 with nucleoside analogs or other HBV core inhibitors on the inhibition of HBV DNA replication in HepG2.2.15 cells. In: EASL, The International Liver Congress 2015; 2015. p. S559","DOI":"10.1016\/S0168-8278(15)30845-X"},{"issue":"2","key":"9661_CR58","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1128\/JVI.02440-14","volume":"89","author":"S Rawat","year":"2015","unstructured":"Rawat S, Bouchard MJ. The hepatitis B virus (HBV) HBx protein activates AKT to simultaneously regulate HBV replication and hepatocyte survival. J Virol 2015;89(2):999\u20131012","journal-title":"J Virol"},{"issue":"12","key":"9661_CR59","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1136\/gutjnl-2011-301073","volume":"61","author":"A Bertoletti","year":"2011","unstructured":"Bertoletti A, Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut 2011;61(12):1754\u20131764","journal-title":"Gut"},{"issue":"6","key":"9661_CR60","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1097\/QCO.0000000000000110","volume":"27","author":"A Bertoletti","year":"2014","unstructured":"Bertoletti A, Rivino L. Hepatitis B: future curative strategies. Curr Opin Infect Dis 2014;27(6):528\u2013534","journal-title":"Curr Opin Infect Dis"},{"issue":"11","key":"9661_CR61","doi-asserted-by":"crossref","first-page":"7269","DOI":"10.1128\/JVI.79.11.7269-7272.2005","volume":"79","author":"M Isogawa","year":"2005","unstructured":"Isogawa M, Robek MD, Furuichi Y, Chisari FV. Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol 2005;79(11):7269\u20137272","journal-title":"J Virol"},{"issue":"6","key":"9661_CR62","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.jhep.2014.12.026","volume":"62","author":"S Menne","year":"2015","unstructured":"Menne S, Tumas DB, Liu KH, Thampi L, AlDeghaither D, Baldwin BH, et al. Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the woodchuck model of chronic hepatitis B. J Hepatol 2015;62(6):1237\u20131245","journal-title":"J Hepatol"},{"issue":"2","key":"9661_CR63","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jhep.2015.02.037","volume":"63","author":"EJ Gane","year":"2015","unstructured":"Gane EJ, Lim Y-S, Gordon SC, Visvanathan K, Sicard E, Fedorak RN, et al. The oral Toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection. J Hepatol 2015;63(2):320\u2013328","journal-title":"J Hepatol"},{"issue":"6","key":"9661_CR64","doi-asserted-by":"crossref","first-page":"e1004210","DOI":"10.1371\/journal.ppat.1004210","volume":"10","author":"J Jo","year":"2014","unstructured":"Jo J, Tan AT, Ussher JE, Sandalova E, Tang X-Z, Tan-Garcia A, et al. Toll-like receptor 8 agonist and bacteria trigger potent activation of innate immune cells in human liver. PLoS Pathog 2014;10(6):e1004210","journal-title":"PLoS Pathog"},{"issue":"1","key":"9661_CR65","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.immuni.2014.12.016","volume":"42","author":"S Sato","year":"2014","unstructured":"Sato S, Li K, Kameyama T, Hayashi T, Ishida Y, Murakami S, et al. The RNA sensor RIG-I dually functions as an innate sensor and direct antiviral factor for hepatitis B virus. Immunity 2014;42(1):123\u2013132","journal-title":"Immunity"},{"issue":"2","key":"9661_CR66","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1128\/JVI.02008-08","volume":"83","author":"H Guo","year":"2009","unstructured":"Guo H, Jiang D, Ma D, Chang J, Dougherty AM, Cuconati A, et al. Activation of pattern recognition receptor-mediated innate immunity inhibits the replication of hepatitis B virus in human hepatocyte-derived cells. J Virol 2009;83(2):847\u2013858","journal-title":"J Virol"},{"issue":"33","key":"9661_CR67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1073\/pnas.1412631111","volume":"111","author":"A Shlomai","year":"2014","unstructured":"Shlomai A, Schwartz RE, Ramanan V, Bhatta A, de Jong YP, Bhatia SN, et al. Modeling host interactions with hepatitis B virus using primary and induced pluripotent stem cell-derived hepatocellular systems. Proc Natl Acad Sci USA 2014;111(33):1\u20136","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"9661_CR68","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/nbt843","volume":"21","author":"T Yamada","year":"2003","unstructured":"Yamada T, Iwasaki Y, Tada H, Iwabuki H, Chuah MKL, VandenDriessche T, et al. Nanoparticles for the delivery of genes and drugs to human hepatocytes. Nat Biotechnol 2003;21(8):885\u2013890","journal-title":"Nat Biotechnol"},{"issue":"5","key":"9661_CR69","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1128\/JVI.01990-10","volume":"85","author":"KSR Sastry","year":"2011","unstructured":"Sastry KSR, Too CT, Kaur K, Gehring AJ, Low L, Javiad A, et al. Targeting hepatitis B virus-infected cells with a T-cell receptor-like antibody. J Virol 2011;85(5):1935\u20131942","journal-title":"J Virol"},{"issue":"6","key":"9661_CR70","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1002\/hep.25875","volume":"56","author":"C Ji","year":"2012","unstructured":"Ji C, Sastry KSR, Tiefenthaler G, Cano J, Tang T, Ho ZZ, et al. Targeted delivery of interferon-\u03b1 to hepatitis B virus-infected cells using T-cell receptor-like antibodies. Hepatology 2012;56(6):2027\u20132038","journal-title":"Hepatology"},{"issue":"4","key":"9661_CR71","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jhep.2009.12.017","volume":"52","author":"MK Maini","year":"2010","unstructured":"Maini MK, Schurich A. The molecular basis of the failed immune response in chronic HBV: therapeutic implications. J Hepatol 2010;52(4):616\u2013619","journal-title":"J Hepatol"},{"issue":"4","key":"9661_CR72","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0168-8278(03)00292-7","volume":"39","author":"C Boni","year":"2003","unstructured":"Boni C, Penna A, Bertoletti A, Lamonaca V, Rapti I, Missale G, et al. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol 2003;39(4):595\u2013605","journal-title":"J Hepatol"},{"issue":"3","key":"9661_CR73","doi-asserted-by":"crossref","first-page":"e1003208","DOI":"10.1371\/journal.ppat.1003208","volume":"9","author":"A Schurich","year":"2013","unstructured":"Schurich A, Pallett LJ, Lubowiecki M, Singh HD, Gill US, Kennedy PT, et al. The third signal cytokine IL-12 rescues the anti-viral function of exhausted HBV-specific CD8 T cells. PLoS Pathog 2013;9(3):e1003208","journal-title":"PLoS Pathog"},{"issue":"2","key":"9661_CR74","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1053\/j.gastro.2009.09.052","volume":"138","author":"P Fisicaro","year":"2010","unstructured":"Fisicaro P, Valdatta C, Massari M, Loggi E, Biasini E, Sacchelli L, et al. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 2010;138(2):682\u2013693.e1\u20134","journal-title":"Gastroenterology"},{"issue":"6","key":"9661_CR75","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.jhep.2014.07.005","volume":"61","author":"B Bengsch","year":"2014","unstructured":"Bengsch B, Martin B, Thimme R. Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation. J Hepatol 2014;61(6):1212\u20131219","journal-title":"J Hepatol"},{"issue":"6","key":"9661_CR76","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1053\/j.gastro.2012.08.041","volume":"143","author":"P Fisicaro","year":"2012","unstructured":"Fisicaro P, Valdatta C, Massari M, Loggi E, Ravanetti L, Urbani S, et al. Combined blockade of programmed death-1 and activation of CD137 increase responses of human liver T cells against HBV, but not HCV. Gastroenterology 2012;143(6):1576\u20131585.e4","journal-title":"Gastroenterology"},{"issue":"5","key":"9661_CR77","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nri2744","volume":"10","author":"LM Weiner","year":"2010","unstructured":"Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010;10(5):317\u2013327","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"9661_CR78","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00430-014-0381-y","volume":"204","author":"M-L Michel","year":"2015","unstructured":"Michel M-L, Bourgine M, Fontaine H, Pol S. Therapeutic vaccines in treating chronic hepatitis B: the end of the beginning or the beginning of the end? Med Microbiol Immunol 2015;204(1):121\u2013129","journal-title":"Med Microbiol Immunol"},{"issue":"1","key":"9661_CR79","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00430-014-0377-7","volume":"204","author":"S Koh","year":"2015","unstructured":"Koh S, Bertoletti A. Circumventing failed antiviral immunity in chronic hepatitis B virus infection: triggering virus-specific or innate-like T cell response? Med Microbiol Immunol 2015;204(1):87\u201394","journal-title":"Med Microbiol Immunol"},{"issue":"12","key":"9661_CR80","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1089\/hum.1998.9.12-1719","volume":"9","author":"M S\u00e4llberg","year":"1998","unstructured":"S\u00e4llberg M, Hughes J, Javadian A, Ronlov G, Hultgren C, Townsend K, et al. Genetic immunization of chimpanzees chronically infected with the hepatitis B virus, using a recombinant retroviral vector encoding the hepatitis B virus core antigen. Hum Gene Ther 1998;9(12):1719\u20131729","journal-title":"Hum Gene Ther"},{"issue":"1","key":"9661_CR81","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1128\/JVI.01505-07","volume":"82","author":"E Depla","year":"2008","unstructured":"Depla E, Van der Aa A, Livingston BD, Crimi C, Allosery K, De Brabandere V, et al. Rational design of a multiepitope vaccine encoding T-lymphocyte epitopes for treatment of chronic hepatitis B virus infections. J Virol 2008;82(1):435\u2013450","journal-title":"J Virol"},{"issue":"6","key":"9661_CR82","doi-asserted-by":"crossref","first-page":"e1003391","DOI":"10.1371\/journal.ppat.1003391","volume":"9","author":"AD Kosinska","year":"2013","unstructured":"Kosinska AD, Zhang E, Johrden L, Liu J, Seiz PL, Zhang X, et al. Combination of DNA prime\u2013adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model. PLoS Pathog 2013;9(6):e1003391","journal-title":"PLoS Pathog"},{"issue":"1","key":"9661_CR83","doi-asserted-by":"crossref","first-page":"e1003856","DOI":"10.1371\/journal.ppat.1003856","volume":"10","author":"J Liu","year":"2014","unstructured":"Liu J, Zhang E, Ma Z, Wu W, Kosinska A, Zhang X, et al. Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection. PLoS Pathog 2014;10(1):e1003856","journal-title":"PLoS Pathog"},{"issue":"9","key":"9661_CR84","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1172\/JCI66043","volume":"123","author":"AJ Gehring","year":"2013","unstructured":"Gehring AJ, Haniffa M, Kennedy PT, Ho ZZ, Boni C, Shin A, et al. Mobilizing monocytes to cross-present circulating viral antigen in chronic infection. J Clin Invest 2013;123(9):3766\u20133776","journal-title":"J Clin Invest"},{"issue":"6","key":"9661_CR85","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/ni.2573","volume":"14","author":"L-R Huang","year":"2013","unstructured":"Huang L-R, Wohlleber D, Reisinger F, Jenne CN, Cheng R-L, Abdullah Z, et al. Intrahepatic myeloid-cell aggregates enable local proliferation of CD8(+) T cells and successful immunotherapy against chronic viral liver infection. Nat Immunol 2013;14(6):574\u2013583","journal-title":"Nat Immunol"},{"issue":"7","key":"9661_CR86","doi-asserted-by":"crossref","first-page":"e1003490","DOI":"10.1371\/journal.ppat.1003490","volume":"9","author":"M Isogawa","year":"2013","unstructured":"Isogawa M, Chung J, Murata Y, Kakimi K, Chisari FV. CD40 activation rescues antiviral CD8+ T cells from PD-1-mediated exhaustion. PLoS Pathog 2013;9(7):e1003490","journal-title":"PLoS Pathog"},{"issue":"3","key":"9661_CR87","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jhep.2013.05.003","volume":"59","author":"D-Z Xu","year":"2013","unstructured":"Xu D-Z, Wang X-Y, Shen X-L, Gong G-Z, Ren H, Guo L-M, et al. Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings. J Hepatol 2013;59(3):450\u2013456","journal-title":"J Hepatol"},{"issue":"2","key":"9661_CR88","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1053\/j.gastro.2013.04.047","volume":"145","author":"K Krebs","year":"2013","unstructured":"Krebs K, B\u00f6ttinger N, Huang L-R, Chmielewski M, Arzberger S, Gasteiger G, et al. T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice. Gastroenterology 2013;145(2):456\u2013465","journal-title":"Gastroenterology"},{"issue":"1","key":"9661_CR89","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jhep.2010.10.025","volume":"55","author":"AJ Gehring","year":"2011","unstructured":"Gehring AJ, Xue S-A, Ho ZZ, Teoh D, Ruedl C, Chia A, et al. Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. J Hepatol 2011;55(1):103\u2013110","journal-title":"J Hepatol"},{"issue":"2","key":"9661_CR90","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2014.10.001","volume":"62","author":"W Qasim","year":"2015","unstructured":"Qasim W, Brunetto M, Gehring AJ, Xue S-A, Schurich A, Khakpoor A, et al. Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient. J Hepatol 2015;62(2):486\u2013491","journal-title":"J Hepatol"},{"key":"9661_CR91","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1038\/mtna.2013.43","volume":"2","author":"S Koh","year":"2013","unstructured":"Koh S, Shimasaki N, Suwanarusk R, Ho ZZ, Chia A, Banu N, et al. A practical approach to immunotherapy of hepatocellular carcinoma using T cells redirected against hepatitis B virus. Mol Ther Nucleic Acids 2013;2:e114","journal-title":"Mol Ther Nucleic Acids"},{"key":"9661_CR92","doi-asserted-by":"crossref","unstructured":"Koh S, Tham CYL, Tanoto AT, Pavesi A, Kamm R, Bertoletti A. Engineered HBV specific T cells: disentangling antiviral from killing capacity. In: EASL, The International Liver Congress 2015; 2015. p. S188","DOI":"10.1016\/S0168-8278(15)30005-2"},{"issue":"12","key":"9661_CR93","doi-asserted-by":"crossref","first-page":"e1003784","DOI":"10.1371\/journal.ppat.1003784","volume":"9","author":"A Bertoletti","year":"2013","unstructured":"Bertoletti A, Gehring AJ. Immune therapeutic strategies in chronic hepatitis B virus infection: virus or inflammation control? PLoS Pathog 2013;9(12):e1003784","journal-title":"PLoS Pathog"},{"issue":"5","key":"9661_CR94","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.jhep.2013.05.040","volume":"59","author":"G Sitia","year":"2013","unstructured":"Sitia G, Iannacone M, Guidotti LG. Anti-platelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma. J Hepatol 2013;59(5):1135\u20131138","journal-title":"J Hepatol"},{"issue":"1","key":"9661_CR95","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hep.27805","volume":"62","author":"T Vanwolleghem","year":"2015","unstructured":"Vanwolleghem T, Hou J, van Oord G, Andeweg AC, Osterhaus ADME, Pas SD, et al. Re-evaluation of hepatitis B virus clinical phases by systems biology identifies unappreciated roles for the innate immune response and B cells. Hepatology 2015;62(1):87\u2013100","journal-title":"Hepatology"},{"key":"9661_CR96","doi-asserted-by":"crossref","first-page":"6588","DOI":"10.1038\/ncomms7588","volume":"6","author":"M Hong","year":"2015","unstructured":"Hong M, Sandalova E, Low D, Gehring AJ, Fieni S, Amadei B, et al. Trained immunity in newborn infants of HBV-infected mothers. Nat Commun 2015;6:6588","journal-title":"Nat Commun"},{"issue":"3","key":"9661_CR97","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1053\/j.gastro.2012.06.009","volume":"143","author":"PTF Kennedy","year":"2012","unstructured":"Kennedy PTF, Sandalova E, Jo J, Gill U, Ushiro-Lumb I, Tan AT, et al. Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B. Gastroenterology 2012;143(3):637\u2013645","journal-title":"Gastroenterology"},{"issue":"3","key":"9661_CR98","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/cmi.2014.95","volume":"12","author":"AJ Gehring","year":"2015","unstructured":"Gehring AJ, Ann D\u2019Angelo J. Dissecting the dendritic cell controversy in chronic hepatitis B virus infection. Cell Mol Immunol 2015;12(3):283\u201391","journal-title":"Cell Mol Immunol"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-015-9661-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12072-015-9661-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-015-9661-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T01:02:27Z","timestamp":1691974947000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12072-015-9661-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,12]]},"references-count":98,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["9661"],"URL":"https:\/\/doi.org\/10.1007\/s12072-015-9661-x","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,12]]}}}